New developments in the treatment of pancreatic cancer

Journal of the Pancreas

Volumn 9, Issue 4, 2008, Pages 391-397

  Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Carcinoma; Fluorouracil; Gemcitabine; Oxaliplatin; Pancreatic ductal; Pancreatic neoplasms; Radiotherapy; Salvage therapy; Treatment failure

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INCIDENCE; LIVER METASTASIS; LYMPH NODE METASTASIS; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE CARE; PROGNOSIS; PROTEINURIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; MULTICENTER STUDIES AS TOPIC; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 48949092304     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Saif MW. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January; 25-27, 2008. JOP. J Pancreas (Online) 2008; 9:91-8.
2. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008 Apr 22.
3. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA4504).
4. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan R K, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4506).
5. Vervenne W, Bennouna J, Humblet Y, Gill S, Moore MJ, Van Laethem J, et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4507).
6. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4508).
7. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP. J Pancreas (Online) 2007; 8:545-52.
8. Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP. J Pancreas (Online) 2007; 8:279-88.
9. Chauffert B, Mornex F, Bonnetain F, Triboulet JP, Bouche 0, Rougier P, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 2006; 24(18S, Part I)A008. ASCO Annual Meeting.
10. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
12. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23:8033-40.
13. Kang SP, Saif MW. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP. J Pancreas (Online) 2008; 9:83-90.